Form 10-Q Intra-Cellular Therapies For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
Intra-Cellular Therapies (ITCI) PT Raised to $79 at Goldman Sachs
October 30, 2024 4:38 PM EDTGoldman Sachs analyst Corinne Jenkins raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $79.00 (from $74.00) while maintaining a Neutral rating.
The analyst comments "Focus remains on commercial execution ahead of MDD launch. ITCI reported 3Q24 revenues of $175.4M, slightly higher than FactSet consensus ($172.3M, +2%) and in-line with GS estimate ($175.2M, 0%). The company also modestly raised and narrowed the range... More
